Consolidated Interim Report 1 January – 30 June 2025
Key points from the H1-2025 report (period 1 January – 30 June 2025)
14 August 2025
Announcement no. 9
On 14 August 2025, the Board of Directors and the Executive Board of Pharma Equity Group A/S (“PEG”, “The Company” or the “Group”) considered and approved the interim report for the Group for the period 1 January – 30 June 2025 (“H1 2025 report”), which can be summarized as follows:
The headlines for the period can be summarized as follows
- The Company has launched a new strategy to drive growth and shareholder returns.
- On 1 April 2025, Christian Henrik Tange was appointed as the new CEO of Pharma Equity Group and Sebastian Bo Jakobsen was appointed as CEO of the subsidiary Reponex Pharmaceuticals A/S
- The company continues the dialogue with potential licensing partners.
- Clinical trial applications for RNX-011 (peritonitis) and the clinical trial application for RNX-051 (Colorectal Adenoma and Colon Cancer) have been submitted to the Danish authorities in H1 2025.
- The profit for the period of 1 January – 30 June 2025 amounts to DKK -9.5 million, which is in line with expectations..
H1-2025 TDKK H1-2024 TDKK
Profit/Loss …